Director, Key Opinion Leader Marketing, Rare Disease

About the role

The Director, Key Opinion Leader Marketing, Rare Disease is a strategic leader within the U.S. Rare Liver Marketing team, responsible for defining and advancing the peer-to-peer engagement strategy across the portfolio. This role serves as the architect of Ipsen's external expert engagement ecosystem, shaping how scientific leaders, advocates, and peer influencers are engaged to advance disease-state education, support earlier diagnosis, inform brand strategy, and drive adoption across existing and future portfolio assets. This role requires deep expertise in external expert engagement, peer-to-peer education, and congress strategy, as well as the scientific acumen, executive presence, and cross-functional leadership necessary to influence senior stakeholders and drive portfolio-wide impact.

Responsibilities

• Peer Engagement Strategy
  • Own and evolve the enterprise peer-to-peer engagement strategy across the U.S. Rare Disease portfolio, ensuring alignment with portfolio growth objectives, competitive dynamics, and future launch priorities.
  • Establish portfolio-level KOL, speaker, and advocate engagement frameworks, segmentation approaches, and investment priorities that maximize scientific influence and educational impact.
  • Build a credible, science-driven peer-to-peer offering aligned to portfolio priorities including tools and resources for TLL team.
  • Prioritize peer-to-peer programs and channels to expand reach and frequency across key stakeholders.
  • Build and manage congress roadmap, capabilities, and continually improve associated processes.
  • Ensure a single, cohesive peer-to-peer experience aligned to brand strategy and priorities.
  • Shape how peer influence is leveraged across the customer journey to support disease-state awareness, diagnosis acceleration, treatment adoption, and launch readiness.
• Portfolio Leadership & Governance
  • Own and continuously evolve the portfolio speaker bureau strategy, governance, and operating model, ensuring alignment to business priorities and maximizing the impact of peer-to-peer engagement investments.
  • Establish governance and oversight for speaker engagement, contracting, fair market value rates, utilization, and HCP transparency practices across the rare disease portfolio.
  • Define and lead the portfolio congress strategy, including prioritization of investments, scientific engagement plans, sponsorship opportunities, and cross-brand activation designed to maximize organizational impact.
  • Direct the design and execution of integrated congress and peer-to-peer engagement plans that advance disease-state education, strengthen scientific leadership, and support portfolio growth objectives.
  • Lead strategic partnerships with agencies and external vendors, ensuring delivery of innovative, high-impact engagement programs while optimizing resource allocation and return on investment.
  • Partner with Medical, PRC, Legal, and Business Ethics to establish governance frameworks and ensure compliant execution of peer engagement activities across the portfolio.
• Insights, Measurement & Leadership
  • Serve as the organization's center of excellence for peer engagement strategy, establishing standards, governance, and best practices across the rare disease portfolio.
  • Define KPIs and measurement to optimize speaker and congress program performance and ROI.
  • Own portfolio speaker bureau and congress budget planning and resource allocation.
  • Ensure on-time and on-budget delivery of congresses and sponsorships.
  • Synthesize insights from KOL interactions, congress engagement, speaker bureau activity, and competitive intelligence to inform portfolio strategy, launch planning, and business decision-making.
  • Establish clear governance, decision-making, and prioritization across the team and partners.
  • Drive alignment with Brand, Sales, TLL, Medical, PRC, and Business Ethics.
  • Influence senior leadership through data-driven recommendations regarding market dynamics, emerging scientific trends, KOL sentiment, and external stakeholder priorities.

Requirements

• Significant experience (12+ years) of commercial pharma experience, including U.S. peer-to-peer, speaker, or HCP marketing roles in rare disease and/or specialty markets.
• Proven success managing a speaker bureau, delivering peer-to-peer programs, and working with KOLs.
• Proven experience planning and executing local, regional, and national congresses.
• Experience building peer-to-peer and speaker programs in rare or ultra-rare diseases.
• Strong understanding of medical, legal, and regulatory (MLR) requirements governing peer-to-peer programs.
• Strong communication and interpersonal skills along with the ability to influence others.
• Demonstrated ability to lead cross-functionally and influence senior stakeholders.
• Strong scientific/medical aptitude and experience including knowledge of complex therapeutic areas and dynamic treatment landscapes.
• Mentally agile and solutions-oriented, with the ability to navigate ambiguity, adapt quickly, and drive practical solutions in a dynamic environment.
• Ability to work with multiple internal cross-functional teams and successfully manage multiple projects simultaneously.
• Knowledge of regulations associated with promotion and industry-supported scientific education activities.
• Working within an environment of strict compliance to all appropriate regulatory guidelines.
• Demonstrated success in project, vendor, and experience managing large budgets.

Qualifications

• Bachelor’s degree (BA/BS) required; Advanced degree (MBA, PharmD, MSc) preferred.
• Fluent in English.

Pay

The annual base salary range for this position is $190,500 - $265,000. This job is eligible to participate in our short-term incentives program.

Benefits

• Comprehensive employee benefits package, including 401(k) with company contributions.
• Group medical, dental, and vision coverage.
• Life and disability insurance, short- and long-term disability insurance.
• Flexible spending accounts.
• Parental leave and paid time off.
• Discretionary winter shutdown.
• Well-being allowance.
• Commuter benefits.